City Hospital, Sandwell & West Birmingham Hospitals NHS Trust, Birmingham, UK.
School of Medicine, University of Nottingham, Nottingham, UK.
Diabetes Obes Metab. 2022 Jul;24(7):1398-1401. doi: 10.1111/dom.14701. Epub 2022 Apr 7.
The ABCD semaglutide audit was designed to capture the routine clinical outcomes of people commenced on semaglutide in the UK. Previous work showed differential reductions in HbA1c and weight dependent on previous glucagon-like peptide-1 receptor agonist (GLP-1RA) exposure. The analysis, in this research letter, shows that decreases in HbA1c and weight associated with semaglutide occur irrespective of previous GLP-1RA use. However, HbA1c reductions were less if switched from dulaglutide or liraglutide and weight changes were attenuated if switched from dulaglutide or exenatide, potentially suggesting differing potencies between GLP-1RAs. Dedicated studies with head-to-head comparisons are needed to confirm these findings.
ABCD 司美格鲁肽审计旨在捕获在英国开始使用司美格鲁肽的人群的常规临床结果。之前的研究表明，HbA1c 和体重的降低与之前胰高血糖素样肽-1 受体激动剂（GLP-1RA）的暴露有关。在这篇研究快报的分析中，结果表明，与使用司美格鲁肽相关的 HbA1c 和体重的降低与之前是否使用 GLP-1RA 无关。然而，如果从度拉鲁肽或利拉鲁肽转换过来，HbA1c 的降低幅度较小，如果从度拉鲁肽或艾塞那肽转换过来，体重的变化则会减弱，这可能表明 GLP-1RAs 之间存在不同的效力。需要进行专门的头对头比较研究来证实这些发现。
